China Approves First Hemophilia B Gene Therapy: BBM-H901 by Belief BioMed and Takeda Belief BioMed and Takeda China have announced the official approval of BBM-H901, the first gene therapy for hemophilia B in China, transforming treatment options for patients.

China Approves First Hemophilia B Gene Therapy: BBM-H901 by Belief BioMed and Takeda #China #Shanghai #Belief_BioMed #Takeda_China #BBM-H901